Growth hormone therapy of Turner's syndrome: Beneficial effect on adult height☆,☆☆,★,★★,♢
Section snippets
Methods
Seventy girls with TS were enrolled in a prospective study, after informed consent had been obtained (Table I). At entry, chronologic age ranged from 4.7 to 12.4 years (mean age, 9.3 years). Mean skeletal age, according to the standards of Greulich and Pyle,7 was 8.0 years, with a maximal bone age of 11.2 years. Chromosome analysis demonstrated a 45,X karyotype in 76% of subjects, structural abnormalities of the X chromosome in 9%, and mosaicism in 15%. Heights at entry were at least 1 standard
Results
Baseline ages, heights, TS height SDS, and mid-parental target heights were not significantly different between the group receiving GH alone and the group receiving combination therapy (Table II).
Empty Cell GH Rx (n = 17) Combination Rx (n = 43) American retrospective control subjects (n = 25) Baseline age (yr) 9.1 (2.1) 9.9 (2.3) 9.2 (1.7) Baseline height (cm) 114.6 (9.5) 17.3 (10.4) 117.1 (8.9) Baseline TS SD score* -0.2 (0.9) -0.2 (0.9) 0.2 (0.9) Baseline Lyon PAH† (cm) 142.0 (5.9) 141.8 (5.9)
Discussion
The mean adult height attained by the retrospective control subjects (144.2 ± 6.0 cm) exactly matched their original mean projected adult heights (144.2 ± 6.1 cm), further validating the use of the method of Lyon et al.9, 10, 11 for projecting adult height in girls with TS. Fifty-eight of the 62 GH-treated subjects (94%) attained adult heights greater than their projected adult heights. The mean adult height for recipients of GH alone was 150.4 cm, 8.4 ± 4.5 cm above their projected adult
References (20)
- et al.
Methionyl human growth hormone and oxandrolone in Turner syndrome: preliminary results of a prospective randomized trial
J Pediatr
(1986) - et al.
Three-year results of a randomized prospective trial of methionyl human growth hormone and oxandrolone in Turner syndrome
J Pediatr
(1988) - et al.
Six-year results of a randomized, prospective trial of human growth hormone and oxandrolone in Turner syndrome
J Pediatr
(1992) - et al.
Physical growth: National Center for Health Statistics percentiles
Am J Clin Nutr
(1979) - et al.
Final height after long-term growth hormone treatment in Turner syndrome
J Pediatr
(1995) - et al.
Chromosomal and clinical findings in 110 females with Turner syndrome
Hum Genet
(1976) - et al.
Growth and maturation of patients with Turner's syndrome
Pediatr Res
(1983) - et al.
Turner's syndrome and growth-promoting therapies
(1991) - et al.
Radiographic atlas of skeletal development of the hand and wrist
(1959) - et al.
Growth curve for girls with Turner syndrome
Arch Dis Child
(1985)
Cited by (256)
Growth Hormone Treatment to Final Height in Turner Syndrome: Systematic Review
2024, Clinical TherapeuticsTurner Syndrome: An Update
2022, Advances in PediatricsTurner Syndrome
2020, Sperling Pediatric Endocrinology: Expert Consult - Online and PrintHuman growth hormone and Turner syndrome
2017, Anales de PediatriaAdult height in Indian girls with turner syndrome treated with long-term growth hormone therapy - A Western India tertiary centre experience
2023, Indian Journal of Endocrinology and Metabolism
- ☆
From the Department of Pediatrics, Oregon Health Sciences University, Portland, Oregon; Genentech, Inc., South San Francisco, California; the Department of Pediatrics, Harbor UCLA Medical Center, Torrance, California; the Department of Pediatrics, University of Tennessee Medical Group, Memphis, Tennessee; the Department of Pediatrics, Henry Ford Hospital, Detroit, Michigan; Children's Hospital Medical Center, Cincinnati, Ohio; the Department of Pediatrics, University of Colorado Medical Center, Denver, Colorado; the Department of Pediatrics, UCLA Medical Center, Los Angeles, California; Children's Hospital and Medical Center, Seattle, Washington; Department of Pediatrics, University of Kansas Medical Center, Kansas City, Kansas; and the Department of Pediatrics, Albert Einstein College of Medicine, Bronx, New York.
- ☆☆
Supported in part by Genentech, Inc., which provided both financial and editorial support (K. M. Attie, J. Frane, J, Kuntze, A. J. Johanson).
- ★
Drs. Rosenfeld, Brasel, and Lippe have been investigators in trials supported by Genentech, Inc. or the Genentech Foundation; Drs. Rosenfeld, Brasel, Cara, Chernausek, Mahoney, Moore, and Saenger have received grants from Genentech or the Genentech Foundation; Drs. Attie, Frane, Johanson and Joyce Kuntz are or have been employees of Genentech, Inc.
- ★★
Reprint requests: Ron G. Rosenfeld, MD, Department of Pediatrics, Oregon Health Sciences University, 3181 S.W. Sam Jackson Park Rd., Portland, OR 97201.
- ♢
9/21/86650